-
Je něco špatně v tomto záznamu ?
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
A. Fanouriakis, M. Kostopoulou, A. Alunno, M. Aringer, I. Bajema, JN. Boletis, R. Cervera, A. Doria, C. Gordon, M. Govoni, F. Houssiau, D. Jayne, M. Kouloumas, A. Kuhn, JL. Larsen, K. Lerstrøm, G. Moroni, M. Mosca, M. Schneider, JS. Smolen, E....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, práce podpořená grantem
NLK
ProQuest Central
od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest)
od 1939-01-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
- MeSH
- biologické přípravky terapeutické užití MeSH
- glukokortikoidy terapeutické užití MeSH
- hydroxychlorochin terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- komorbidita MeSH
- lidé MeSH
- management nemoci MeSH
- medicína založená na důkazech metody MeSH
- stupeň závažnosti nemoci MeSH
- systémový lupus erythematodes komplikace farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- směrnice pro lékařskou praxi MeSH
Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.
Cliniques Universitaires Saint Luc Université catholique de Louvain Brussels Belgium
Cyprus League Against Rheumatism Aglantzia Cyprus
Department of Autoimmune Diseases Hospital Clinic Barcelona Spain
Department of Dermatology and Allergy University Hospital Bonn Bonn Germany
Department of Medicine Addenbrooke's Hospital Cambridge UK
Department of Nephrology G Gennimatas General Hospital Athens Greece
Department of Pathology Leiden University Medical Center Leiden Netherlands
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Division of Rheumatology Department of Medicine 3 Medical University of Vienna Vienna Austria
Nephrology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Rheumatology and Clinical Immunology Unit Attikon University Hospital Athens Greece
Rheumatology and Clinical Immunology University of Brescia Brescia Italy
Rheumatology Clinical Immunology and Allergy University Hospital of Heraklion Heraklion Greece
Rheumatology Unit Department of Clinical and Experimental Medicine University of Pisa Pisa Italy
Rheumatology Unit Department of Medicine University of Padova Padova Italy
Rheumatology Unit Department of Medicine University of Perugia Perugia Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006499
- 003
- CZ-PrNML
- 005
- 20200518132715.0
- 007
- ta
- 008
- 200511s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2019-215089 $2 doi
- 035 __
- $a (PubMed)30926722
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Fanouriakis, Antonis $u Rheumatology and Clinical Immunology Unit, "Attikon" University Hospital, Athens, Greece afanour@med.uoa.gr.
- 245 10
- $a 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus / $c A. Fanouriakis, M. Kostopoulou, A. Alunno, M. Aringer, I. Bajema, JN. Boletis, R. Cervera, A. Doria, C. Gordon, M. Govoni, F. Houssiau, D. Jayne, M. Kouloumas, A. Kuhn, JL. Larsen, K. Lerstrøm, G. Moroni, M. Mosca, M. Schneider, JS. Smolen, E. Svenungsson, V. Tesar, A. Tincani, A. Troldborg, R. van Vollenhoven, J. Wenzel, G. Bertsias, DT. Boumpas,
- 520 9_
- $a Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.
- 650 _2
- $a biologické přípravky $x terapeutické užití $7 D001688
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a medicína založená na důkazech $x metody $7 D019317
- 650 _2
- $a glukokortikoidy $x terapeutické užití $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydroxychlorochin $x terapeutické užití $7 D006886
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a systémový lupus erythematodes $x komplikace $x farmakoterapie $7 D008180
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kostopoulou, Myrto $u Department of Nephrology, "G. Gennimatas" General Hospital, Athens, Greece.
- 700 1_
- $a Alunno, Alessia $u Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.
- 700 1_
- $a Aringer, Martin $u Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
- 700 1_
- $a Bajema, Ingeborg $u Department of Pathology, Leiden University Medical Center, Leiden, Netherlands.
- 700 1_
- $a Boletis, John N $u Nephrology Department and Renal Transplantation Unit, "Laikon" Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
- 700 1_
- $a Cervera, Ricard $u Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain.
- 700 1_
- $a Doria, Andrea $u Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
- 700 1_
- $a Gordon, Caroline $u Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
- 700 1_
- $a Govoni, Marcello $u Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Azienda Ospedaliero-Universitaria Sant'Anna Ferrara, Ferrara, Italy.
- 700 1_
- $a Houssiau, Frédéric $u Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
- 700 1_
- $a Jayne, David $u Department of Medicine, Addenbrooke's Hospital, Cambridge, UK.
- 700 1_
- $a Kouloumas, Marios $u Cyprus League Against Rheumatism, Aglantzia, Cyprus.
- 700 1_
- $a Kuhn, Annegret $u University Hospital Muenster, Muenster, Germany.
- 700 1_
- $a Larsen, Janni L $u Copenhagen Lupus and Vasculitis Clinic, Rheumatology and Spine Diseases Centre, Rigshospitalet, Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Lerstrøm, Kirsten $u Lupus Europe, Farum, Denmark.
- 700 1_
- $a Moroni, Gabriella $u Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- 700 1_
- $a Mosca, Marta $u Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- 700 1_
- $a Schneider, Matthias $u Department of Rheumatology & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany.
- 700 1_
- $a Smolen, Josef S $u Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Svenungsson, Elisabet $u Department of Medicine, Rheumatology Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Tesar, Vladimir $u Department of Nephrology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
- 700 1_
- $a Tincani, Angela $u Rheumatology and Clinical Immunology, University of Brescia, Brescia, Italy.
- 700 1_
- $a Troldborg, Anne $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
- 700 1_
- $a van Vollenhoven, Ronald $u Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
- 700 1_
- $a Wenzel, Jörg $u Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
- 700 1_
- $a Bertsias, George $u Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece.
- 700 1_
- $a Boumpas, Dimitrios T $u Rheumatology and Clinical Immunology Unit, "Attikon" University Hospital, Athens, Greece. Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. Joint Academic Rheumatology Program, Medical School, National and Kapodestrian University of Athens, Athens, Greece and Medical School, University of Cyprus, Nicosia, Cyprus.
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 78, č. 6 (2019), s. 736-745
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30926722 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200518132715 $b ABA008
- 999 __
- $a ok $b bmc $g 1525357 $s 1096555
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 78 $c 6 $d 736-745 $e 20190329 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20200511
